NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered ...
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new initiative with Bristol Myers Squibb (NYSE: BMY). This collaboration ...
RBM20 truncating variants ( RBM20 tvs) appear to contribute to arrhythmogenic dilated cardiomyopathy (DCM) but with ...
The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data update for both ...
Scientists who focus only on generating data risk missing their role in shaping strategy and driving innovation.
Patients with idiopathic intracranial hypertension lost weight and had fewer headaches with GLP-1 receptor agonists, ...
An at-home, mail-in, finger-stick blood test detected Alzheimer’s-related biomarkers associated with cognitive performance in ...
Researchers developed a model to predict risk of TIPN in patients with early-stage cancer treated with a taxane regimen.
Researchers demonstrated that self-administered fingerprick blood tests measuring p-tau217 and GFAP, returned by post, ...
Longer 24-hour systolic blood pressure time-in-target range is associated with a reduced risk for all-cause and cardiovascular mortality.
The null finding held up even when researchers sliced the data by geography, income, insurance type, and social vulnerability ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results